EMA streamlines procedures amid 'challenging' economic climate
This article was originally published in SRA
Executive Summary
Faced with budget constraints and an ever-growing workload, the European Medicines Agency is reorganizing its internal processes in a bid to make them more efficient while increasing the overall quality of its work1. The move includes the creation of two new senior positions to allow individual products to be more closely shepherded through the EMA drug evaluation process.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.